News
-
-
PRESS RELEASE
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
AB Science announces new publication on medRxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in amyotrophic lateral sclerosis patients -
-
-
-
-
-
PRESS RELEASE
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041, positioning it uniquely and competitively in the treatment landscape -
-
PRESS RELEASE
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
AB Science's patent for masitinib in the treatment of sickle cell disease is formally granted in the United States, providing long-term protection until 2040. The biomarker Phase 2 in cooperation with AP-HP is fully funded
